Hematology: Trials and tribulations in primary CNS lymphoma

Stephen M Ansell et al. Nat Rev Clin Oncol. 2010 Mar.

. 2010 Mar;7(3):125-6.

doi: 10.1038/nrclinonc.2010.9.

No abstract available

Comment in

Flows and flaws in primary central nervous system lymphoma.
Ferreri AJ, Illerhaus G, Zucca E, Cavalli F; International Extranodal Lymphoma Study Group. Ferreri AJ, et al. Nat Rev Clin Oncol. 2010 Aug;7(8):doi:10.1038/nrclinonc.2010.9-c1; author reply doi:10:1038/nrclinonc.2010.9-c2. doi: 10.1038/nrclinonc.2010.9-c1. Nat Rev Clin Oncol. 2010. PMID: 20700952 No abstract available.

The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment.
Wong Doo N, White VM, Martin K, Bassett JK, Prince HM, Harrison SJ, Jefford M, Winship I, Millar JL, Milne RL, Seymour JF, Giles GG. Wong Doo N, et al. Cancers (Basel). 2019 Jul 2;11(7):928. doi: 10.3390/cancers11070928. Cancers (Basel). 2019. PMID: 31269764 Free PMC article.
Flows and flaws in primary central nervous system lymphoma.
Ferreri AJ, Illerhaus G, Zucca E, Cavalli F; International Extranodal Lymphoma Study Group. Ferreri AJ, et al. Nat Rev Clin Oncol. 2010 Aug;7(8):doi:10.1038/nrclinonc.2010.9-c1; author reply doi:10:1038/nrclinonc.2010.9-c2. doi: 10.1038/nrclinonc.2010.9-c1. Nat Rev Clin Oncol. 2010. PMID: 20700952 No abstract available.
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.
Ferreri AJ, Licata G, Foppoli M, Corazzelli G, Zucca E, Stelitano C, Zaja F, Fava S, Paolini R, Franzin A, Politi LS, Ponzoni M, Reni M. Ferreri AJ, et al. Oncologist. 2011;16(3):336-41. doi: 10.1634/theoncologist.2010-0361. Epub 2011 Feb 23. Oncologist. 2011. PMID: 21346023 Free PMC article. Clinical Trial.